Gilead misses key goal in NASH liver disease trial
Analysts have projected the market for NASH treatments to reach $20 billion to $35 billion as populations with fatty diets…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Sun Pharma announces ILUMYATM data at American Academy of Dermatology 2019 Annual Meeting
ILUMYATM three-year data demonstrates sustained skin clearance in patients with moderate-to-severe plaque psoriasis
Merck, Pfizer drug combo extends kidney cancer survival: Study
Merck released interim data from the trial, saying the combination reduced the risk of death by 47 per cent compared with Sutent
Wockhardt gets US FDA for generic prostrate cancer drug
The drug will be launched in the US market soon
AYUSH Minister to lay foundation stone for National Institute of Unani Medicine at Ghaziabad
Once established, the NIUM, Ghaziabad, with a 200-bedded hospital, would be one of the largest institutes of Unani Medicine in…
USTR review could mean tough times ahead
Withdrawal of the GSP scheme could hit the industry quite hard
IDMA bags ‘India Pharma Swachhatta Champion Award’
IDMA Secretariat at Mumbai had conducted a cleanliness drive on 10th September, 2018 at B Y L Nair Charitable Hospital as part of…
Lupin launches chronic angina treatment drug in the US
The newly-launched product, in strengths of 500 mg and 1,000 mg, is a generic version of Gilead Sciences' Ranexa ER tablets
Govt brings 42 non-scheduled cancer drugs under price control
Currently, 57 anti-cancer drugs are under price control as scheduled formulations